Henry Moore, MD
Payments from drug & device makers
Across 445 payments — averaging $2335.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$525K
- Amneal Pharmaceuticals LLC$168K
- Neurocrine Biosciences, Inc.$162K
- Sunovion Pharmaceuticals Inc.$112K
- Teva Pharmaceuticals USA, Inc.$35K
- Ipsen Biopharmaceuticals, Inc$12K
- plus $25K from 20 others
Across 7 payments — averaging $7928.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$45K
- Neurocrine Biosciences, Inc.$10K
What the payments were for
- Consulting fees$14,04636%
- Speaking & faculty fees$12,25731%
- Travel & lodging$4,34411%
- Food & beverage$8,22721%
- Education$1720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 27 | $525,248 |
| Amneal Pharmaceuticals LLC | 37 | $168,375 |
| Neurocrine Biosciences, Inc. | 202 | $162,013 |
| Sunovion Pharmaceuticals Inc. | 57 | $112,437 |
| Teva Pharmaceuticals USA, Inc. | 16 | $35,077 |
| Ipsen Biopharmaceuticals, Inc | 6 | $11,659 |
| Acadia Pharmaceuticals Inc | 14 | $9,387 |
| AbbVie(2 entities) | 26 | $8,920 |
| Medtronic(2 entities) | 21 | $2,303 |
| Lundbeck LLC | 3 | $1,886 |
| Abbott | 4 | $396 |
| Merz Pharmaceuticals, LLC | 8 | $369 |
| Kyowa Kirin, Inc. | 4 | $284 |
| UCB, Inc. | 3 | $147 |
| MDD US Operations, LLC | 2 | $140 |
| Adamas Pharmaceuticals, Inc. | 2 | $129 |
| Supernus Pharmaceuticals, Inc. | 2 | $126 |
| Boston Scientific | 2 | $121 |
| Genentech, Inc. | 1 | $91 |
| Biogen | 2 | $86 |
| Revance Therapeutics, Inc. | 1 | $75 |
| Amgen | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,039,368 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 70 | $566,784 |
| NuplazidPimavanserin Tartrate | 103 | $554,858 |
| GocovriAmantadine Hcl | 33 | $173,425 |
| RytaryCarbidopa/Levodopa | 107 | $152,314 |
| AustedoDeutetrabenazine | 28 | $149,166 |
| Austedo XrDeutetrabenazine | 15 | $72,225 |
| InbrijaLevodopa | 18 | $52,630 |
| NeuproRotigotine | 24 | $32,522 |
| OngentysOpicapone | 21 | $21,640 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 596 | $19,515 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,036 |
| Entacapone | 44 | $12,997 |
| Rasagiline Mesylate | 66 | $12,179 |
| CrexontCarbidopa/Levodopa | 15 | $11,938 |
| Rivastigmine | 39 | $8,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $162,013 | $588,42591 claims |
| Acadia Pharmaceuticals IncNuplazid | $9,387 | $554,858103 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $35,077 | $221,39143 claims |
| MDD US Operations, LLCGocovri | $140 | $173,42533 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $168,375 | $164,252122 claims |
| Acorda Therapeutics, IncInbrija | $17 | $52,63018 claims |
| UCB, Inc.Neupro | $147 | $32,52224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Miami
- Michael PfefferMiami$24.5M
- Silvia DelgadoMiami$11M
- Angel CarrascoMiami$10.3M
- Michael BenatarMiami$5.4M
- Kottil RammohanMiami$5M
- Macarena de la FuenteMiami$4.9M
- Victor FaradjiMiami$4M
- Brad HerskowitzMiami$3.1M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.